Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City
Ethnicity and Disease · 2023
DOI: 10.18865/1653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ethnicity and Disease, 2023. Verfasst von Ofole Mgbako und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Objective
To compare clinical characteristics and examine in-hospital length of stay (LOS) differences for COVID-19 patients who received remdesivir, by race or ethnicity.
Design
Retrospective descriptive analysis comparing cumulative LOS as a proxy of recovery time.
Setting
A large academic medical center serving a minoritized community in Northern Manhattan, New York City.
Participants
Inpatients (N=1024) who received remdesivir from March 30, 2020–April 20, 2021.
Methods
We conducted descriptive analyses among patients who received remdesivir. Patients were described by proxies of social determinants of health (SDOH): race and ethnicity, residence, insurance coverage, and clinical characteristics. We calculated median hospital LOS as the cumulative incidence of hospitalized patients who were discharged alive, and tested differences between groups by using the Gray test. Patients who died or were discharged to hospice were censored at 29 days. Main Outcome Measures The primary outcome was hospital LOS. The secondary outcome was in-hospital mortality.
Results
Median LOS was 11.9 days (95% CI, 10.8-13.2) overall, with Black patients having the shortest (10.0 days, 95% CI, 8.0-13.2) and Asian patients having the longest (16.2 days, 95% CI, 8.3-27.2) LOS. A total of 214 patients (21%) died or were discharged to hospice, ranging from 16.5% to 23.7% of patients who identified as Black and Other (multiracial, biracial, declined), respectively.
Conclusions
COVID-19 has disproportionately burdened communities of color. We observed no difference in median LOS between racial or ethnic groups, which supports the notion that the heterogeneous effect of remdesivir in the literature may be explained in part by underrecruitment or participation of Black, Hispanic, and Asian patients in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, NYU Langone Health, New York, NY.
- NYU Institute for Excellence in Health Equity, NYU Langone Health, New York, NY.
- Department of Pharmacy, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY.
- Division of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
- Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY.
- Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
Förderung
- NIMH NIH HHS
- NIAID NIH HHS
Zitieren
APA
Mgbako, O., Mehta, M., Dietz, D., Neidell, M. J., Huang, S. E., Zucker, J., Shoucri, S., Kubin, C. J., & Castor, D. (2023). Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City. Ethnicity and Disease. https://doi.org/10.18865/1653
Vancouver
Mgbako O, Mehta M, Dietz D, Neidell MJ, Huang SE, Zucker J, et al. Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City. Ethnicity and Disease. 2023. doi:10.18865/1653
BibTeX
@article{Mgbako2023,
author = {Mgbako, Ofole and Mehta, Monica and Dietz, Donald and Neidell, Matthew J and Huang, Simian Esther and Zucker, Jason and Shoucri, Sherif and Kubin, Christine J and Castor, Delivette},
title = {Race and Remdesivir: Examination of Clinical Outcomes in a Racially and Ethnically Diverse Cohort in New York City},
journal = {Ethnicity and Disease},
year = {2023},
doi = {10.18865/1653}
}
EUVIMED